Duvelisib was the 2nd PI3K inhibitor accredited by the FDA, also based upon a period III randomized trial.130 The efficacy and protection profile from the drug surface equivalent with People of idelalisib, Otherwise marginally useful. Relating to substitute BTK inhibitors, there are many products in development, but only acalabrutinib is authorised